Craft Telemedicine today announced the official launch of its innovative telemedicine platform that eliminates subscription models and empowers patients with unprecedented choice and transparency in their healthcare decisions. Unlike traditional...
Alafair Biosciences, Inc., a leading innovator in medical device technology, is pleased to announce the first patient enrolled at UC Davis Foot and Ankle Orthopaedics Clinic, as part of a prospective, multi-center, controlled case series...
support options for individuals at every stage of their health journey. The expanded product lineup includes MIC+B12 injections that support metabolic health and energy production, as well as two new oral combination therapies: Metformin +...
multi-cohort, Phase 2 LEGEND trial to establish its safety and efficacy in high-risk NMIBC. LEGEND’s pivotal cohort (Cohort 1) consists of approximately 100 patients with high-risk, BCG-unresponsive NMIBC with CIS (with or without papillary...
LLC announced positive topline results from its confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed biosimilar to XOLAIR® (omalizumab). The randomized, double-blind, multicenter study assessed the efficacy and...
trial support. With the world’s largest commercially available patient-derived xenograft (PDX) collection and approximately 1,000 tumor organoid models powered by Hubrecht Organoid Technology, we offer unparalleled insights across 35 cancer...
for customers. Globally, more than 80% of novel drugs have been submitted to regulatory authorities using Empower Software.1 With this release, the Alliance iS HPLC System delivers leading touchscreen security by offering individual and...
full confidence that their animal care and facility operations meet the highest standards. About SoBran, Inc. Founded in 1987, SoBran, Inc. provides professional services in bioscience, engineering, logistics, and security. The company is dedicated...
will be carried first aboard Phoenix—a re-entry capable, small-scale free-flyer developed by ATMOS-, and ultimately REV1, full-scale free flyer developed by Space Cargo Unlimited to enable frequent and cost-effective research in space. "Space Cargo...
Investigator Award. Lung cancer is responsible for more deaths worldwide than any other cancer, accounting for an estimated 130,180 deaths annually in the United States alone.1 In the last 10 to 15 years, accelerated clinical trials and FDA...
trial, 360 adults with severe, uncontrolled CRSwNP and coexisting asthma were randomized to receive Dupixent 300 mg (n=181) every two weeks or a weight- and immunoglobulin E (IgE) level-based dosing regimen of Xolair (n=179) every two or four...
Dr. Fouad Chebib. ADPKD, a prevalent genetic disorder characterized by the growth of numerous kidney cysts, affects about 1 in 400 to 1,000 people worldwide. The disease progressively impairs kidney function, often leading to kidney failure....
aligned in the mission to improve patient outcomes through targeted cancer therapies and diagnostics." Incorporated in 1995, Macrocyclics is a CDMO specialized in chelating agents for radiopharmaceuticals and nuclear medicine. The company maintains...
Samsung Biologics a leading contract development and manufacturing organization (CDMO), today announced the launch of Samsung Organoids – advanced drug screening services to support clients in drug discovery and development. Organoids are...
Genmab A/S announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab, ifosfamide, carboplatin, and...
which can be used in an assortment of downstream assays tailored to customer needs. Currently the platform processes >1,000 samples per year with routinely >96% success rate and is expected to multiply the output of patient-derived iPSC-derived...
(FDA) has approved IBTROZI™ (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). IBTROZI is a highly selective, next-generation oral ROS1 tyrosine kinase...
also includes potential future indications. Avanzanite is rapidly scaling its operations, having tripled its revenue in Q1 2025 year-over-year, with two rare disease medicines already on the market. Over the next 12 months, the company will expand...
Lubrizol announces that an Apisolex™ polymer excipient-enabled drug formulation is in Phase 1 clinical trials. Introduced to the market in 2022, Apisolex polymer excipient is a polyamino acid-based polymer that enhances the solubility of BCS Class...
These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan,...
